Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

被引：50

作者：

Agache, Ioana ^{[1
]}

Rocha, Claudio ^{[2
]}

Pereira, Ana ^{[2
]}

Song, Yang ^{[2
]}

Alonso-Coello, Pablo ^{[3
,4
]}

Sola, Ivan ^{[2
]}

Beltran, Jessica ^{[2
]}

Posso, Margarita ^{[3
]}

Akdis, Cezmi ^{[5
,6
]}

Akdis, Mubeccel ^{[5
,6
]}

Brockow, Knut ^{[7
]}

Chivato, Tomas ^{[8
]}

del Giacco, Stefano ^{[9
]}

Eiwegger, Thomas ^{[10
,11
,12
,13
]}

Eyerich, Kilian ^{[14
]}

Gimenez-Arnau, Ana ^{[15
]}

Gutermuth, Jan ^{[16
]}

Guttman-Yassky, Emma ^{[17
]}

Maurer, Marcus ^{[18
]}

Ogg, Graham ^{[19
]}

Ong, Peck ^{[20
]}

O'Mahony, Liam ^{[21
,22
]}

Schwarze, Jurgen ^{[23
]}

Werfel, Thomas ^{[24
]}

Canelo-Aybar, Carlos ^{[3
,4
]}

Palomares, Oscar ^{[25
]}

Jutel, Marek ^{[26
,27
]}

机构：

[1] Transylvania Univ, Fac Med, 2A Pictor Ion Andreescu, Brasov 500051, Romania

[2] Biomed Res Inst St Pau IIB St Pau, Dept Clin Epidemiol & Publ Hlth, Iberoamer Cochrane Ctr, Barcelona, Spain

[3] IMIM Hosp del Mar Med Res Inst, Dept Epidemiol & Evaluat, Barcelona, Spain

[4] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain

[5] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland

[6] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland

[7] Tech Univ Munich, Dept Dermatol & Allergol Biederstein, Munich, Germany

[8] Univ CEU San Pablo, Med, Madrid, Spain

[9] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy

[10] Hosp Sick Children, Res Inst, Translat Med Program, Toronto, ON, Canada

[11] Univ Toronto, Dept Immunol, Toronto, ON, Canada

[12] Univ Toronto, Hosp Sick Children, Food Allergy & Anaphylaxis Program, Div Immunol & Allergy,Dept Paediat, Toronto, ON, Canada

[13] Univ Toronto, Hosp Sick Children, Food Allergy & Anaphylaxis Program, Div Immunol & Allergy,Dept Immunol, Toronto, ON, Canada

[14] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany

[15] Univ Autonoma Barcelona, Hosp del Mar, Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain

[16] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel, Dept Dermatol, Brussels, Belgium

[17] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

[18] Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Dermatol Allergol, Berlin, Germany

[19] Univ Oxford, Weatherall Inst Mol Med, Dept Med, MRC Human Immunol Unit, Oxford, England

[20] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA

[21] Univ Coll Cork, APC Microbiome Ireland, Dept Med, Cork, Ireland

[22] Univ Coll Cork, APC Microbiome Ireland, Dept Microbiol, Cork, Ireland

[23] Univ Edinburgh, Ctr Inflammat Res Child Life & Hlth, Edinburgh, Midlothian, Scotland

[24] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany

[25] Univ Complutense Madrid, Chem Sch, Dept Biochem & Mol Biol, Madrid, Spain

[26] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland

[27] ALL MED Med Res Inst, Wroclaw, Poland

来源：

ALLERGY | 2021年 / 76卷 / 01期

关键词：

chronic idiopathic urticaria; chronic spontaneous urticaria; itch severity score; omalizumab; urticaria activity score; CHRONIC IDIOPATHIC URTICARIA; DISEASE-ACTIVITY; IMPORTANT DIFFERENCE; QUALITY; GRADE; SERUM;

D O I：

10.1111/all.14547

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95%CI -3.22 to -0.81) and decreases (moderate certainty) rescue medication use (MD -1.68; 95%CI -2.95 to -0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5) and decreases (moderate certainty) rescue medication use (MD -2.04; 95%CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).

引用

页码：59 / 70

页数：12

共 50 条

[21] Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
Sirufo, Maria Maddalena
Bassino, Enrica Maria
De Pietro, Francesca
Ginaldi, Lia
De Martinis, Massimo
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2021, 35
[22] Profile of omalizumab in the treatment of chronic spontaneous urticaria
Labrador-Horrillo, Moises
Ferrer, Marta
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4909 - 4915
[23] Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria
Tabanlioglu-Onan, Duru
Oktem, Ayse
Yalcin, Basak
Artuz, Ferda
ASTIM ALLERJI IMMUNOLOJI, 2019, 17 (01): : 41 - 46
[24] Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
Yan, Che-Wen
Cho, Yung-Tsu
Chu, Chia-Yu
DERMATOLOGICA SINICA, 2017, 35 (04) : 182 - 186
[25] Omalizumab in the treatment of chronic spontaneous urticaria - literature review and own experience
Dawicka, Joanna
Wilkowska, Aleksandra
Grubska-Suchanek, Elzbieta
Nowicki, Roman
PRZEGLAD DERMATOLOGICZNY, 2016, 103 (01): : 64 - 70
[26] Omalizumab re-treatment rates in chronic spontaneous urticaria
Khan, S.
Sholtysek, S.
EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 52 (04) : 187 - 189
[27] Psychosocial factors and chronic spontaneous urticaria: a systematic review
Donnelly, Jennifer
Ridge, Katie
O'Donovan, Roisin
Conlon, Niall
Dunne, Padraic J.
BMC PSYCHOLOGY, 2023, 11 (01)
[28] Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab
Watanabe, Haruka
Takahagi, Shunsuke
Hayama, Koremasa
Fukunaga, Atsushi
Nakagawa, Yukinobu
Inomata, Naoko
Chinuki, Yuko
Hide, Michihiro
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, : 349 - 358
[29] Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases
Subramaniyan, Radhakrishnan
Chopra, Ajay
INDIAN JOURNAL OF DERMATOLOGY, 2016, 61 (04) : 467
[30] Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment
Urgert, M. C.
van den Elzen, M. T.
Knulst, A. C.
Fedorowicz, Z.
van Zuuren, E. J.
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (02) : 404 - 415

← 1 2 3 4 5 →